NEUCHATEL, SWITZERLAND--(Marketwired - Oct 10, 2014) - Masimo (NASDAQ: MASI), maker of breakthrough Masimo SET ® Measure-through Motion and Low Perfusion™ Pulse Oximetry, today announced the CE Mark ...

NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse ...

Masimo MASI recently reported findings from the NeoPODS study, a large prospective real-world evaluation of its SET pulse oximetry technology in critically ill newborns. The study demonstrated less ...

Masimo Corporation (NASDAQ:MASI) received the FDA’s nod for its RD SET sensors to be used with Masimo Measure-through Motion and Low Perfusion SET pulse oximetry. The procedure is aimed at offering ...

ZURICH, SWITZERLAND and IRVINE, CA--(Marketwired - Nov 22, 2013) - Masimo (NASDAQ: MASI) announced today that ACUTRONIC Medical Systems AG has integrated Masimo SET ® Measure-through Motion and Low ...

Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET ® pulse oximetry among ...

Smaller, Flexible Sensors Are More Comfortable for Patients, Easier to Apply for Clinicians "Masimo's new low-profile sensors are not only flatter and easier to apply, but the added pliability allows ...

Masimo’s revolutionary SET® pulse oximetry has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies – even before the revisions that achieved ...

Masimo today announced the results of a prospective study published in the International Journal of Neonatal Screening in which researchers in Marrakesh, Morocco, conducted the first Moroccan study on ...

Recent announcements highlight major sensor innovations: a faster chip-based system for detecting free radicals, the first 3D atomic charge map of a key sensing material, and a large-scale study ...